Aclaris Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Clinical-stage specialty pharmaceutical company focused on dermatology. The filing covers the quarter and six months ended June 30, 2016, and was filed August 11, 2016. Lead candidate A-101 was in three Phase 3 trials for seborrheic keratosis, with enrollment completed in the second quarter. Aclaris also pursued A-101 for common warts, A-102, and JAK inhibitors for alopecia areata and other conditions.
Financial condition and results
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0 in 2016 and 2015 | $0 in 2016 and 2015 |
| Research and development expense | $9.8 million vs. $1.8 million | $19.4 million vs. $3.5 million |
| General and administrative expense | $3.2 million vs. $0.8 million | $6.8 million vs. $1.7 million |
| Net loss | $12.9 million vs. $2.6 million | $25.9 million vs. $5.2 million |
| Net loss per share | $0.62 vs. $1.52 | $1.27 vs. $3.04 |
| Operating cash flow | Not separately presented | $(16.6) million vs. $(5.7) million |
At June 30, 2016, cash and cash equivalents were $31.8 million, marketable securities were $62.2 million, and total liquidity was $94.0 million. Total assets were $96.1 million, total liabilities were $5.9 million, and stockholders’ equity was $90.2 million. The company reported no debt or material credit facilities. Accumulated deficit was $68.7 million.
Investing activities provided $20.0 million, principally from sales and maturities of marketable securities. Financing activities provided $18.5 million from a June 2016 private placement of 1.1 million common shares. Cash increased by $22.0 million during the first six months, ending at $31.8 million.
Material changes versus the prior comparable period
- R&D spending increased $15.8 million for the six-month period, driven by Phase 3 A-101 trials, JAK inhibitor development, the Vixen acquisition, additional personnel, and stock-based compensation.
- G&A spending increased $5.1 million for the six-month period, reflecting higher headcount, public-company costs, stock-based compensation, market research, Vixen-related expenses, and a $0.3 million A-101 milestone payment.
- The March 2016 Vixen acquisition added JAK-related intellectual property and resulted in $3.4 million of six-month R&D expense, including cash and non-cash acquisition-related amounts.
- The company raised $20.0 million gross, or $18.5 million net, in a June 2016 private placement.
- Per-share loss decreased despite the higher aggregate loss because the weighted-average share count increased substantially following the IPO and other equity issuances.
Guidance, outlook, risks and unusual items
Management expected continued net losses and higher R&D expenses as clinical development progressed. Subject to favorable Phase 3 results, Aclaris planned to submit an NDA for A-101 for seborrheic keratosis in the first quarter of 2017 and expected initial results from the common-warts Phase 2 trial in the third quarter of 2016.
Management stated that existing cash, cash equivalents and marketable securities were expected to fund operating and capital requirements for more than 12 months from June 30, 2016 under current assumptions. Additional financing was expected to be required for commercialization, continued development, and potential acquisitions or licenses. Failure to obtain financing could require delaying, reducing, or discontinuing programs.
- Clinical trial outcomes, enrollment, regulatory review, manufacturing, commercialization, and market acceptance remain uncertain.
- Intellectual property protection is uncertain, and certain A-101 patents were scheduled to expire in 2022. License breaches could result in loss of rights to JAK-related technologies.
- Contingent obligations included up to $80.0 million in pre-commercialization milestones and $10.0 million in additional development milestones under the Rigel license, plus milestone and royalty obligations under other license and acquisition agreements.
- Future contractual commitments included approximately $0.9 million of sublease payments through 2019, a $1.0 million payment upon submission of the A-101 NDA, and additional contingent Vixen, Columbia, and intellectual-property payments.
- The company had no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of June 30, 2016.
Important facts for investors to verify
- Whether A-101 Phase 3 results supported the planned first-quarter 2017 NDA submission.
- Actual cash-burn rates and the duration of the stated greater-than-12-month liquidity runway.
- The size and timing of future equity, debt, collaboration, or other financing needs.
- Development progress, regulatory status, and intellectual-property coverage for A-101 and the JAK inhibitor programs.
- Potential milestone, royalty, license, acquisition, and commercialization obligations that could materially increase future cash requirements.